The presence of these iDAMPs suggests that therapeutic GET provides a dual advantage: not only are constitutive DAMPs released from dying cells, but tumour-resident antigen-presenting cells such as dendritic cells and macrophages can also be activated by iDAMPs, thereby promoting efficient CD8+ T-cell cross-priming within the tumour microenvironment.90,91. The gene discussed is CD8A; the disease is neoplasm.